Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

A new study by UCSF researchers reveals that long-acting injectable treatments offer a promising alternative for HIV patients who find it challenging to adhere to daily pill regimens. This ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

T'puram: A group of four unidentified assailants vandalized a medical shop in Neyyattinkara after the shopkeeper refused to sell them sleeping pills without a doctor's prescription. The incident ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study.

Mumbai (Maharashtra) [India], March 10: On the occasion of International Women's Day, FCB Group India and RK HIV AIDS Research and Care Centre organized a Maha Arogya Shivir, a free general ...

A small French biotech is trumpeting results from a trial suggesting its developmental drug could be used as part of an HIV cure. The phase 2a trial of AbiVax’s ABX464 pill is small but confirms ...

Einstein’s general theory of relativity can be summed up in just 12 words: “Space-time tells matter how to move; matter tells space-time how to curve”. But this short description from the ...

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro.